CA2690746C - Phenothizine compounds for treating mild cognitive impairment - Google Patents

Phenothizine compounds for treating mild cognitive impairment Download PDF

Info

Publication number
CA2690746C
CA2690746C CA2690746A CA2690746A CA2690746C CA 2690746 C CA2690746 C CA 2690746C CA 2690746 A CA2690746 A CA 2690746A CA 2690746 A CA2690746 A CA 2690746A CA 2690746 C CA2690746 C CA 2690746C
Authority
CA
Canada
Prior art keywords
use according
diaminophenothiazine compound
mtc
treatment
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2690746A
Other languages
English (en)
French (fr)
Other versions
CA2690746A1 (en
Inventor
Claude Michel Wischik
Dominic Venay Harbaran
Gernot Riedel
Serena Deiana
Elizabeth Anne Goatman
Damon Jude Wischik
Alison Dorothy Murray
Roger Todd Staff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CA2690746A1 publication Critical patent/CA2690746A1/en
Application granted granted Critical
Publication of CA2690746C publication Critical patent/CA2690746C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2690746A 2007-06-19 2008-06-17 Phenothizine compounds for treating mild cognitive impairment Active CA2690746C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
US60/945,006 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (2)

Publication Number Publication Date
CA2690746A1 CA2690746A1 (en) 2008-12-24
CA2690746C true CA2690746C (en) 2018-01-02

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2690746A Active CA2690746C (en) 2007-06-19 2008-06-17 Phenothizine compounds for treating mild cognitive impairment

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104606199B (zh) 2006-03-29 2022-09-13 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
DK2205245T3 (en) * 2007-10-03 2015-09-28 Wista Lab Ltd Therapeutic use of diaminophenothiaziner
JP5868955B2 (ja) 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド 抗ウイルス化合物
CA2827027C (en) 2011-02-11 2019-06-04 Wista Laboratories Ltd. Phenothiazine diaminium salts and their use
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
EP3686181B1 (en) * 2013-01-30 2024-07-17 Ecolab USA Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
DK3258938T3 (da) * 2015-02-17 2021-02-01 Univ Arizona State Phenothiazinanaloger som mitokondrie terapeutiske midler
PT3487505T (pt) 2016-07-25 2023-06-07 Wista Lab Ltd Administração e dosagem de diaminofenotiazinas
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
JP7465861B2 (ja) 2018-07-26 2024-04-11 ウィスタ ラボラトリーズ リミテッド 集団におけるジアミノフェノチアジンの最適化投与
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
CA3257856A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT)
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
US20070037848A1 (en) * 2003-04-03 2007-02-15 Masters Colin L Treatment of neurological conditions
JP5186212B2 (ja) * 2004-09-23 2013-04-17 ウィスタ ラボラトリーズ リミテッド メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法
ES2409683T3 (es) * 2004-09-23 2013-06-27 Wista Laboratories Ltd. Procedimientos de síntesis química y purificación de compuestos de diaminofenotiazinio que incluyen cloruro de metiltioninio (CMT)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
CN104606199B (zh) 2006-03-29 2022-09-13 维斯塔实验室有限公司 3,7-二氨基-10h-吩噻嗪化合物盐及其用途
DK2001556T3 (da) * 2006-03-29 2014-11-10 Wista Lab Ltd Thioninium-forbindelser og anvendelse deraf
DK2004155T3 (en) 2006-03-29 2018-04-30 Wista Lab Ltd PROTEIN AGGREGATION INHIBITORS
CN101511803B (zh) * 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法

Also Published As

Publication number Publication date
US20100184752A1 (en) 2010-07-22
ES2739546T3 (es) 2020-01-31
HUE045460T2 (hu) 2019-12-30
CA2690746A1 (en) 2008-12-24
MY177001A (en) 2020-09-01
WO2008155533A3 (en) 2009-02-19
PT2167095T (pt) 2019-08-06
US9211294B2 (en) 2015-12-15
CN101820884A (zh) 2010-09-01
AU2008265045B2 (en) 2014-02-27
EP2167095A2 (en) 2010-03-31
JP2010530403A (ja) 2010-09-09
DK2167095T3 (da) 2019-07-29
SI2167095T1 (sl) 2019-09-30
HRP20191513T1 (hr) 2019-11-29
AU2008265045A1 (en) 2008-12-24
CN101820884B (zh) 2013-08-28
PL2167095T3 (pl) 2019-11-29
WO2008155533A2 (en) 2008-12-24
JP5725605B2 (ja) 2015-05-27
EP2167095B1 (en) 2019-05-29
BRPI0813670A2 (pt) 2014-12-30

Similar Documents

Publication Publication Date Title
AU2008265045B2 (en) Phenothiazine compounds for treating Mild Cognitive Impairment
KR102654569B1 (ko) 외상 후 스트레스 장애의 치료를 위한 제제
CN107810002B (zh) 左乙拉西坦的延时释放药物组合物
JP7686581B2 (ja) 認知機能の向上薬としてのメチルチオニニウム
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
EA037187B1 (ru) Способ и композиция для лечения когнитивного расстройства
US20190231768A1 (en) Pridopidine for treating drug induced dyskinesias
US20250302773A1 (en) Compositions comprising meai and n-acylethanolamines and uses thereof
CA2740029C (en) Pharmaceutical composition for treatment of fibromyalgia
HK1136965B (en) Phenothiazine compounds for treating mild cognitive impairment
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment
US20220008388A1 (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
JP2019519480A (ja) パーキンソン病患者において転倒を低減するためのアセチルコリンエステラーゼ阻害剤およびイダロピルジンの使用
WO2023243659A1 (ja) 線条体ストリオソームのドパミンｄ１シグナルを標的とした強迫性障害の薬物療法
HK40052880A (en) Extended release pharmaceutical compositions of levetiracetam
HK40065529A (en) Combination of gaboxadol and lithium for the treatment of psychiatric disorders
Yohn Induction and Treatment of Motivational Dysfunctions in a Rodent Pharmacological Model of Effort-Related Choice Behavior: Evidence from Behavioral and Neurochemical Studies
HK1252154B (zh) 左乙拉西坦的延时释放药物组合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130524

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250528

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250528